BPA Call 36E79720A0019-36C25721N0069
Award Date 10/16/20
Potential Completion Date 10/16/21
Potential Value $284K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lake Mary, FL 32746, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration awarded a delivery order to Novartis Pharmaceuticals Corp., doing business as NPS, for the specialized cancer medication KYMRIAH (TISAGENLECLEUCEL). The $283,526.57 firm fixed price order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and extends through August 2025. Novartis, a foreign-owned for-profit manufacturer, has...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the chimeric antigen receptor T-cell therapy drug Kymriah. The order, valued at $283,567.92, was placed against Novartis' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and has a firm fixed price. The order supports the VA's medical programs and does not have a...
- The Department of Veterans Affairs (VA) awarded a $283,526.57 firm fixed price delivery order to Novartis Pharmaceuticals Corporation, a foreign-owned for-profit manufacturer, to provide the emergency cancer treatment Tisagenlecleucel under the VA's Federal Supply Schedule contract for pharmaceuticals and drugs. The delivery order was issued by the VA Veterans Health Administration's Veterans Integrated Service Network 9 and did not have a set-aside designation. Novartis holds a $5.4 billion...
- This firm fixed-price delivery order was awarded by the Department of Veterans Affairs Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the Kymriah chimeric antigen receptor T-cell therapy to the Nashville VA Medical Center. The order, valued at $283,526.57, was issued against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion. Kymriah is a...
- This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer of pharmaceutical goods. The contract, valued at $231,396.00, is a Delivery Order contract with a Firm Fixed Price pricing type. The contract is for the procurement of specialized medical treatments, such as cancer therapies and advanced pharmaceuticals, to support the VA's medical programs. The contract utilizes the...
- This federal contract award is for the delivery of the radiopharmaceutical PLUVICTO to the Cleveland VA Medical Center (VAMC). The $598,124.52 firm fixed price delivery order was issued against Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB). Novartis, a foreign-owned for-profit manufacturer, has provided specialized cancer therapies like Kymriah to VA networks and facilities under previous orders and agreements. This...
- This federal contract award, valued at $1,596,998.62, was issued by the Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation, a large, foreign-owned pharmaceutical manufacturer. The contract is a delivery order under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and will provide the VA with the cancer therapy drug PLUVICTO through September 30, 2026. Novartis holds a $5.4 billion FSS contract for pharmaceuticals and drugs, as well as a $21.5 million...
- This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation (Novartis), a foreign-owned, for-profit manufacturer of pharmaceutical products. The $283,526.57 order is for Novartis' cell therapy treatment Tisagenlecleucel, which is used to treat certain types of cancer. The order was placed through Novartis' existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB), which allows the VA to...
- The Department of Veterans Affairs (VA) awarded a $283,526.57 delivery order to Novartis Pharmaceuticals Corporation, doing business as NPS, for emergency drug orders to support the Tennessee Valley Healthcare System (TVHS). This order was placed against Novartis' Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. Novartis, a foreign-owned, for-profit manufacturer, has provided specialized...
- This is a federal contract award by the Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation, a large, foreign-owned pharmaceutical manufacturer. The contract is a firm fixed-price delivery order worth $736,610 for the delivery of the cancer treatment drug PLUVICTO. The contract utilizes the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of August 4, 2026. The contract does not have a small business set-aside...